Digestive Diseases and Sciences

, Volume 52, Issue 2, pp 502–507 | Cite as

Effect of Naloxone-3-Glucuronide and N-Methylnaloxone on the Motility of the Isolated Rat Colon After Morphine

  • Peter Reber
  • Rudolf Brenneisen
  • Beatrice Flogerzi
  • Catarina Batista
  • Peter Netzer
  • Ulrich Scheurer
Original Paper


The effect of the opioid antagonists naloxone-3-glucuronide and N-methylnaloxone on rat colon motility after morphine stimulation was measured. The rat model consisted of the isolated, vascularly perfused colon. The antagonists (10−4 M, intraluminally) and morphine (10−4 M, intra-arterially) were administered from 20 to 30 and from 10 to 50 min, respectively. Colon motility was determined by the luminal outflow. The antagonist concentrations in the luminal and venous outflow were measured by high-performance liquid chromatography. Naloxone-3-glucuronide and N-methylnaloxone reversed the morphine-induced reduction of the luminal outflow to baseline within 10 and 20 min, respectively. These antagonists were then excreted in the luminal outflow and could not be found in the venous samples. Naloxone, produced by hydrolysis or demethylation, was not detectable. In conclusion, highly polar naloxone derivatives peripherally antagonize the motility-lowering effect of morphine in the perfused isolated rat colon, are stable, and are not able to cross the colon-mucosal blood barrier.


Isolated rat colon Morphine Motility inhibition Naloxone-3-glucuronide N-Methylnaloxone Opioid receptor antagonists 



This study was supported by Grant 3200–066693.01 from the Swiss National Science Foundation.


  1. 1.
    Vanegas G, Ripamonti C, Sbanotto A, De Conno F (1998) Side effects of morphine administration in cancer patients. Cancer Nurs 21:289–297PubMedCrossRefGoogle Scholar
  2. 2.
    Grond S, Zech D, Diefenbach C, Bischoff A (1994) Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 9:372–382PubMedCrossRefGoogle Scholar
  3. 3.
    Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B (1992) A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage 7:259–266PubMedCrossRefGoogle Scholar
  4. 4.
    Holmes S (1989) Use of a modified symptom distress scale in assessment of the cancer patient. Int J Nurs Stud 26:69–79PubMedCrossRefGoogle Scholar
  5. 5.
    Simpkins JW, Smulkowski M, Dixon R, Tuttle R (1988) Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther 244:195–205PubMedGoogle Scholar
  6. 6.
    Pappagallo M (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:11S–18SPubMedCrossRefGoogle Scholar
  7. 7.
    Fallon MT, Hanks GW (1999) Morphine, constipation and performance status in advanced cancer patients. Palliat Med 13:159–160PubMedCrossRefGoogle Scholar
  8. 8.
    De Luca A, Coupar IM (1996) Insights into opioid action in the intestinal tract. Pharmacol Ther 69:103–115PubMedCrossRefGoogle Scholar
  9. 9.
    Porreca F, Cowan A, Raffa RB, Tallarida RJ (1983) Ketazocines and morphine: effects on gastrointestinal transit after central and peripheral administration. Life Sci 32:1785–1790PubMedCrossRefGoogle Scholar
  10. 10.
    Galligan JJ, Burks TF (1983) Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat. J Pharmacol Exp Ther 226:356–361PubMedGoogle Scholar
  11. 11.
    Manara L, Bianchi G, Ferretti P, Tavani A (1986) Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther 237:945–949PubMedGoogle Scholar
  12. 12.
    Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J (1997) The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 61:467–475PubMedCrossRefGoogle Scholar
  13. 13.
    Bartlett SE, Dodd PR, Smith MT (1994) Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacol Toxicol 75:73–81PubMedGoogle Scholar
  14. 14.
    Christrup LL (1997) Morphine metabolites. Acta Anaesthesiol Scand 41:116–122PubMedGoogle Scholar
  15. 15.
    Ulens C, Baker L, Ratka A, Waumans D, Tytgat J (2001) Morphine-6beta-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies. Biochem Pharmacol 62:1273–1282PubMedCrossRefGoogle Scholar
  16. 16.
    Meunier A, Latremoliere A, Mauborgne A, et al. (2005) Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther 11:608–616PubMedCrossRefGoogle Scholar
  17. 17.
    Comert M, Sipahi EY, Ustun H, et al. (2005) Morphine modulates inducible nitric oxide synthase expression and reduces pulmonary oedema induced by alpha-naphthylthiourea. Eur J Pharmacol 511:183–189PubMedCrossRefGoogle Scholar
  18. 18.
    Lewanowitsch T, Irvine RJ (2002) Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal. Eur J Pharmacol 445:61–67PubMedCrossRefGoogle Scholar
  19. 19.
    Maslov LN, Lishmanov YB, Solenkova NV, Gross GJ, Stefano GB, Tam SW (2003) Activation of peripheral delta opioid receptors eliminates cardiac electrical instability in a rat model of post-infarction cardiosclerosis via mitochondrial ATP-dependent K+ channels. Life Sci 73:947–952PubMedCrossRefGoogle Scholar
  20. 20.
    Menendez L, Lastra A, Meana A, Hidalgo A, Baamonde A (2005) Analgesic effects of loperamide in bone cancer pain in mice. Pharmacol Biochem Behav 81:114–121PubMedCrossRefGoogle Scholar
  21. 21.
    Herrmann C, Cuber JC, Dakka T, Bernard C, Chayvialle JA (1991) Bombesin potentiates taurocholic acid-induced neurotensin release in rats. Endocrinology 128:2853–2857PubMedCrossRefGoogle Scholar
  22. 22.
    Herrmann-Rinke C, Eissele R, Arnold R, Goke B (1996) Studies on the viability of the isolated vascularly perfused rat colon. Digestion 57:349–355PubMedCrossRefGoogle Scholar
  23. 23.
    Reber PU, Patel AG, Lewis MP, Ashley SW, Reber HA (1998) Stenting does not decompress the pancreatic duct as effectively as surgery in experimental chronic pancreatitis. Surgery 124:561–567PubMedGoogle Scholar
  24. 24.
    Scheurer U, Drack E, Halter F (1985) Cyclooxygenase inhibitors affect Met-enkephalin- and acetylcholine-stimulated motility of the isolated rat colon. J Pharmacol Exp Ther 234:742–746PubMedGoogle Scholar
  25. 25.
    Scheurer U, Wenger F, Caliezi A, Drack E, Varga L, Halter F (1990) Different motor actions of dynorphins and nonpeptide kappa opioid receptor agonists in the isolated rat colon. J Pharmacol Exp Ther 252:1324–1330PubMedGoogle Scholar
  26. 26.
    Lenard L Jr., Halmai V, Bartho L (1999) Morphine contracts the guinea pig ileal circular muscle by interfering with a nitric oxide mediated tonic inhibition. Digestion 60:562–566PubMedCrossRefGoogle Scholar
  27. 27.
    Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K (2000) Oral naloxone reverses opioid-associated constipation. Pain 84:105–109PubMedCrossRefGoogle Scholar
  28. 28.
    Sykes NP (1996) An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 10:135–144PubMedGoogle Scholar
  29. 29.
    Jurna I, Kaiser R, Kretz O, Baldauf J (1992) Oral naloxone reduces constipation but not antinociception from oral morphine in the rat. Neurosci Lett 142:62–64PubMedCrossRefGoogle Scholar
  30. 30.
    Bianchi G, Fiocchi R, Tavani A, Manara L (1982) Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity. Life Sci 30:1875–1883PubMedCrossRefGoogle Scholar
  31. 31.
    Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J (1996) Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 59:469–475PubMedCrossRefGoogle Scholar
  32. 32.
    Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J (1999) Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain 83:631–635PubMedCrossRefGoogle Scholar
  33. 33.
    Yuan CS, Foss JF, O'Connor M, et al. (2000) Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 283:367–372PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Peter Reber
    • 1
  • Rudolf Brenneisen
    • 2
  • Beatrice Flogerzi
    • 3
  • Catarina Batista
    • 2
  • Peter Netzer
    • 3
  • Ulrich Scheurer
    • 3
  1. 1.Department of Vascular SurgeryLindenhof HospitalBernSwitzerland
  2. 2.Department of Clinical ResearchUniversity of BernBernSwitzerland
  3. 3.Clinic for GastroenterologyUniversity HospitalBernSwitzerland

Personalised recommendations